Vomiren 0.5 mg is indicated for the treatment of:
🛒 How to order this item?
100% Genuine Products, Guaranteed
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
Show More
Palonosetron belongs to the therapeutic class of anti-emetic drugs and works by blocking serotonin receptors in the body. The usual dosage varies depending on the indication and route of administration, but it is typically administered orally or intravenously. It is generally safe for use in adults and children, with precautions and dosage adjustments recommended for specific populations such as the elderly, pediatric patients, and those with renal or hepatic impairment.
Interaction with alcohol is unknown
Vomiren 0.5mg Tablet is not recommended for use in pregnant women unless necessary. All the risks and benefits should be discussed with the doctor before taking this medicine.
Vomiren 0.5mg Tablet is not recommended for use in breastfeeding women unless necessary. All the risks and benefits should be discussed with the doctor before taking this medicine. Your doctor may advise you to discontinue breastfeeding for a specific period or may prescribe an alternative medicine based on your clinical condition.
Caution is advised when driving or operating machinery.
There is no interaction between renal impairment and consuming this drug. So dose alteration is not needed.
There is no interaction between the Liver and consuming this drug. So dose alteration is not needed.
Vomiren 0.5mg Tablet blocks the action of certain natural substances that can trigger nausea and vomiting.
Palonosetron is used to control nausea and vomiting that occurs as a result of chemotherapy (treatment of cancer) and is also used for Postoperative nausea and vomiting following surgery in adults.
Chemotherapeutic agents can induce nausea and vomiting by triggering the release of serotonin (5-HT) from enterochromaffin cells in the small intestine. This released serotonin then activates 5-HT3 receptors located on vagal afferents, initiating the vomiting reflex. Similarly, postoperative nausea and vomiting can result from various factors related to the patient, surgery, and anesthesia, leading to the release of serotonin (5-HT) and subsequent activation of neuronal pathways in both the central nervous system and the gastrointestinal tract.
The 5-HT3 receptor plays a crucial role in mediating these emetic responses. Vomiren 0.5 mg acts as a 5-HT3 receptor antagonist, meaning it competes with serotonin for binding to these receptors. By binding strongly to the 5-HT3 receptor and having little or no affinity for other receptors, Vomiren 0.5 mg effectively inhibits the binding of serotonin to these receptors. This inhibition prevents the activation of the vomiting reflex, thereby reducing or preventing nausea and vomiting.
The typical dosage regimen for Vomiren 0.5 mg varies depending on the indication and age of the patient:
Adult Tablet Dosage: For general adult use, the recommended dosage is 0.5 mg taken orally once daily.
Adult IV Dosage: For intravenous administration in adults:
Children Dosage: For pediatric patients aged 1 month to 17 years, the dosage for IV administration is based on body weight:
In clinical trials, Vomiren 0.5 mg injection has been safely combined with various medications, including corticosteroids, analgesics, antiemetics/antinauseants, antispasmodics, and anticholinergic agents. It's noteworthy that Vomiren 0.5 mg did not interfere with the anticancer activity of drugs such as cisplatin, cyclophosphamide, cytarabine, doxorubicin, and mitomycin C in murine tumor models.
Moreover, when administered concurrently with metoclopramide, Vomiren 0.5 mg showed no significant pharmacokinetic interactions. In vitro studies further support the safety profile of Vomiren 0.5 mg, indicating that it does not inhibit the activity of various cytochrome P450 enzymes, including CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, CYP2E1, and CYP3A4/5. Additionally, it does not induce the activity of CYP1A2, CYP2D6, or CYP3A4/5. As a result, the likelihood of clinically significant drug interactions with Vomiren 0.5 mg appears to be low.
These findings provide reassurance regarding the safety and compatibility of Vomiren 0.5 mg with other medications commonly used in clinical practice, particularly in patients requiring concurrent treatment for various conditions. However, as with any medication, it's essential to consult healthcare professionals regarding potential drug interactions before initiating therapy.
Vomiren 0.5 mg is contraindicated in patients known to have hypersensitivity to the drug or any of its components.
US FDA Pregnancy category B. It is not known whether Paloxiron is excreted in human milk
Patients with intestinal obstruction or ileus should avoid using this medication. Rapid injection may cause temporary visual changes such as blurred vision. Individuals with prolonged QT intervals should exercise caution when using this medication. Safety and efficacy have not been established in children under 18 years of age. Patients who perform skilled tasks, such as driving, should be advised that their abilities may be impaired. For lactating individuals, the effects on nursing infants are unknown; therefore, it is recommended to discontinue the drug or refrain from nursing while using it.
Keep in a dry place, away from light and heat.
Disclaimer:
ePharma sole intention is to ensure that its consumers get proper
information as musch as possible. Although we do not guarantee the
accuracy and the completeness of the information that provided and
here information is for informational purposes only.
The information contained herein should NOT be used as a substitute
for the advice of a qualified physician. This may not cover
everything about particular health conditions,
lab tests, medicines, all possible side effects, drug interactions,
warnings, alerts, etc. Please consult your healthcare professional
and discuss all your queries related to any disease or medicine. We
intend to support, not replace, the doctor-patient relationship.